Cellectar Biosciences 향후 성장

Future 기준 점검 0/6

Cellectar Biosciences은 연간 수입과 매출이 각각 55%와 59.5% 증가할 것으로 예상되고 EPS는 연간 63%만큼 증가할 것으로 예상됩니다.

핵심 정보

55.0%

이익 성장률

62.98%

EPS 성장률

Biotechs 이익 성장	23.1%
매출 성장률	59.5%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	10 Mar 2026

최근 향후 성장 업데이트

Recent updates

Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects

Apr 04Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies based on its phospholipid drug conjugate platform for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?

Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve

Mar 20Catalysts About Cellectar Biosciences Cellectar Biosciences is a radiopharmaceutical company focused on phospholipid drug conjugates for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?

Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook

Mar 05Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies for difficult to treat cancers using its proprietary phospholipid drug conjugate platform. What are the underlying business or industry changes driving this perspective?

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30

이익 및 매출 성장 예측

NasdaqCM:CLRB - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	55	-12	N/A	N/A	3
12/31/2027	11	-28	N/A	N/A	3
12/31/2026	N/A	-29	N/A	N/A	3
12/31/2025	N/A	-22	-23	-23	N/A
9/30/2025	N/A	-19	-30	-30	N/A
6/30/2025	N/A	-29	-35	-35	N/A
3/31/2025	N/A	-25	-44	-44	N/A
12/31/2024	N/A	-45	-48	-48	N/A
9/30/2024	N/A	-50	-47	-46	N/A
6/30/2024	N/A	-53	-46	-45	N/A
3/31/2024	N/A	-62	-39	-39	N/A
12/31/2023	N/A	-43	-33	-32	N/A
9/30/2023	N/A	-45	-31	-30	N/A
6/30/2023	N/A	-36	-29	-29	N/A
3/31/2023	N/A	-33	-28	-27	N/A
12/31/2022	N/A	-32	-25	-25	N/A
9/30/2022	N/A	-27	-23	-22	N/A
6/30/2022	N/A	-25	-22	-22	N/A
3/31/2022	N/A	-24	-23	-23	N/A
12/31/2021	N/A	-24	-23	-23	N/A
9/30/2021	N/A	-22	-22	-22	N/A
6/30/2021	N/A	-20	-19	-19	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-15	-14	-14	N/A
9/30/2020	N/A	-15	-13	-13	N/A
6/30/2020	N/A	-15	-13	-13	N/A
3/31/2020	N/A	-14	-12	-12	N/A
12/31/2019	N/A	-14	-12	-12	N/A
9/30/2019	N/A	-15	N/A	-12	N/A
6/30/2019	N/A	-16	N/A	-11	N/A
3/31/2019	N/A	-16	N/A	-11	N/A
12/31/2018	N/A	-15	N/A	-11	N/A
9/30/2018	N/A	-17	N/A	-12	N/A
6/30/2018	N/A	-15	N/A	-11	N/A
3/31/2018	N/A	-16	N/A	-11	N/A
12/31/2017	N/A	-15	N/A	-11	N/A
9/30/2017	N/A	-15	N/A	-11	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-9	N/A	-8	N/A
9/30/2016	N/A	-3	N/A	-7	N/A
6/30/2016	N/A	-2	N/A	-7	N/A
3/31/2016	N/A	-2	N/A	-8	N/A
12/31/2015	N/A	-5	N/A	-8	N/A
9/30/2015	N/A	-10	N/A	-9	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CLRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CLRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CLRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CLRB 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: CLRB 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CLRB의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/06 15:54
종가	2026/04/02 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cellectar Biosciences, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Kumaraguru Raja	Brookline Capital Markets
Keith Markey	Griffin Securities
Aydin Huseynov	Ladenburg Thalmann & Company

Cellectar Biosciences 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 29% to US$33.33

Price target decreased by 48% to US$4.00

Price target decreased by 26% to US$5.67

No longer forecast to breakeven

Price target increased by 23% to US$14.75

Forecast to breakeven in 2026

Recent updates

Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects

Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve

Price target decreased by 29% to US$33.33

Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook

Cellectar Biosciences, Inc. to Report Fiscal Year 2025 Results on Mar 04, 2026

Cellectar Biosciences Expands Global Intellectual Property Estate

Cellectar Biosciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Cellectar Biosciences, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

Cellectar Biosciences Presents Positive Preclinical Data in Poster Presentation At the American Association for Cancer Research Special Conference on Pancreatic Cancer Research

Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm)

Cellectar Biosciences, Inc. Presents Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Cellectar Biosciences, Inc. to Participate At Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions At the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

New major risk - Financial position

Cellectar Biosciences, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Cellectar Biosciences, Inc. has completed a Composite Units Offering in the amount of $5.999997 million.

New major risk - Market cap size

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

New major risk - Shareholder dilution

Cellectar Biosciences Provides Update on Clover-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Price target decreased by 48% to US$4.00

Cellectar Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million.

Cellectar Biosciences, Inc. Grants U.S. Fda Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia

Cellectar Biosciences, Inc. to Report Q1, 2025 Results on May 13, 2025

Cellectar Biosciences, Inc., Annual General Meeting, Jun 13, 2025

New major risk - Financial position

Cellectar Biosciences, Inc. to Report Fiscal Year 2024 Results on Mar 13, 2025

Price target decreased by 26% to US$5.67

Insufficient new directors

Cellectar Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Cellectar Biosciences, Inc. announced delayed 10-Q filing

Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024

Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical